Dr. John Pesando, MD

NPI: 1477150969
Total Payments
$12.8M
2024 Payments
$2.4M
Companies
2
Transactions
84

Payment Breakdown by Category

Royalty/License$12.8M (100.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Royalty or License $12.8M 84 100.0%

Top Paying Companies

Company Total Records Latest Year
Beckman Coulter, Inc. $12.3M 10 $0 (2024)
Becton, Dickinson and Company $468,239 74 $0 (2024)

Payment History by Year

Year Amount Transactions Top Company
2024 $2.4M 18 Beckman Coulter, Inc. ($2.2M)
2023 $2.8M 15 Beckman Coulter, Inc. ($2.6M)
2022 $2.7M 18 Beckman Coulter, Inc. ($2.6M)
2021 $2.5M 17 Beckman Coulter, Inc. ($2.5M)
2020 $2.4M 16 Beckman Coulter, Inc. ($2.4M)

All Payment Transactions

84 individual payment records from CMS Open Payments — Page 4 of 4

Date Company Product Nature Form Amount Type
07/27/2020 Becton, Dickinson and Company BD Pharmingen (Device) Royalty or License Cash or cash equivalent $11.25 General
Category: Cell Analysis
04/27/2020 Becton, Dickinson and Company BD Pharmingen (Device) Royalty or License Cash or cash equivalent $8,706.36 General
Category: Cell Analysis
04/27/2020 Becton, Dickinson and Company BD Pharmingen (Device) Royalty or License Cash or cash equivalent $7,221.31 General
Category: Cell Analysis
04/27/2020 Becton, Dickinson and Company BD Pharmingen (Device) Royalty or License Cash or cash equivalent $414.28 General
Category: Cell Analysis
04/14/2020 Beckman Coulter, Inc. NAVIOS (Device), FC 500 SERIES, AQUIOS CL Royalty or License Cash or cash equivalent $2,054,051.47 General
Category: FLOW CYTOMETRY
04/14/2020 Beckman Coulter, Inc. NAVIOS (Device), FC 500 SERIES, AQUIOS CL Royalty or License Cash or cash equivalent $296,660.66 General
Category: FLOW CYTOMETRY
02/27/2020 Becton, Dickinson and Company BD Pharmingen (Device) Royalty or License Cash or cash equivalent $9,457.66 General
Category: Cell Analysis
02/27/2020 Becton, Dickinson and Company BD Pharmingen (Device) Royalty or License Cash or cash equivalent $6,190.25 General
Category: Cell Analysis
02/27/2020 Becton, Dickinson and Company BD Pharmingen (Device) Royalty or License Cash or cash equivalent $214.68 General
Category: Cell Analysis

About Dr. John Pesando, MD

Dr. John Pesando, MD is a Hematology & Oncology healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/07/2020. The National Provider Identifier (NPI) number assigned to this provider is 1477150969.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Pesando, MD has received a total of $12.8M in payments from pharmaceutical and medical device companies, with $2.4M received in 2024. These payments were reported across 84 transactions from 2 companies. The most common payment nature is "Royalty or License" ($12.8M).

Practice Information

  • Specialty Hematology & Oncology
  • Location Seattle, WA
  • Active Since 10/07/2020
  • Last Updated 10/07/2020
  • Taxonomy Code 207RH0003X
  • Entity Type Individual
  • Practice Solo Practitioner
  • NPI Number 1477150969

Products in Payments

  • NAVIOS (Device) $6.6M
  • Cytomics FC500 (Device) $2.6M
  • FC 500 SERIES (Device) $2.2M
  • CYTOFLEX (Device) $617,470
  • AQUIOS (Device) $330,204
  • Horizon (Device) $234,086
  • BD Pharmingen (Device) $120,867
  • FACSVia (Device) $27,555
  • BD OptiBuild (Device) $22,629

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Hematology & Oncology Doctors in Seattle